Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
about
Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.miR-223 increases gallbladder cancer cell sensitivity to docetaxel by downregulating STMN1.High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens.BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy.High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.
P2860
Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Retrospective analysis of seco ...... all cell lung cancer patients.
@en
type
label
Retrospective analysis of seco ...... all cell lung cancer patients.
@en
prefLabel
Retrospective analysis of seco ...... all cell lung cancer patients.
@en
P2093
P2860
P50
P1476
Retrospective analysis of seco ...... mall cell lung cancer patients
@en
P2093
B Biernacka
J Milanowski
P2860
P2888
P356
10.1007/S12094-015-1333-8
P577
2015-07-07T00:00:00Z